Our platform’s versatility was validated through the correction of additional cancer-associated mutations in SMAD4, PTEN, and KRAS, demonstrating its broader applicability in dissecting the functional roles of diverse genetic alterations (Additional file 2: Fig. S9). This evidence concerns the gene SMAD4 and cancer.